2.37
-0.23(-8.85%)
Currency In USD
| Previous Close | 2.6 |
| Open | 2.68 |
| Day High | 2.68 |
| Day Low | 2.36 |
| 52-Week High | 896 |
| 52-Week Low | 2.35 |
| Volume | 383,749 |
| Average Volume | 203,196 |
| Market Cap | 2.86M |
| PE | -0.01 |
| EPS | -173.82 |
| Moving Average 50 Days | 6.13 |
| Moving Average 200 Days | 19.56 |
| Change | -0.23 |
If you invested $1000 in CERo Therapeutics Holdings, Inc. (CERO) since IPO date, it would be worth $0.12 as of October 17, 2025 at a share price of $2.37. Whereas If you bought $1000 worth of CERo Therapeutics Holdings, Inc. (CERO) shares 3 years ago, it would be worth $0.12 as of October 17, 2025 at a share price of $2.37.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
GlobeNewswire Inc.
Oct 15, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company, announces that Chris Ehrlich, Chief Executive Officer will part
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
GlobeNewswire Inc.
Oct 13, 2025 12:30 PM GMT
Study’s Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval Company issues correction of recently published article, asserts it is not for sale and is no
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
GlobeNewswire Inc.
Sep 22, 2025 1:15 PM GMT
Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISCO, Calif, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CER